Renal Dose Adjustments and Safety Considerations for Dyspepsia Management in Stage 4 CKD

Medication Dose Adjustments

• Ranitidine should be dose‑adjusted in patients with an estimated glomerular filtration rate (eGFR) of ~22 mL/min, following consensus recommendations for renally cleared drugs. 1
• When creatinine clearance is < 30 mL/min, the ranitidine dose should be reduced or the dosing interval extended to avoid accumulation. 1

Contraindicated or Cautious‑Use Medications

• Antibiotics that are contraindicated at eGFR < 30 mL/min—such as those commonly used in Helicobacter pylori eradication regimens—should be avoided in this population. 1
• Nitrofurantoin is prohibited for patients with creatinine clearance < 30 mL/min because of the high risk of toxicity. 1
• Cotrimoxazole requires dose adjustment and careful monitoring when prescribed to individuals with eGFR ≈ 22 mL/min. 1

Monitoring Requirements for Proton Pump Inhibitor (PPI) Therapy

• Patients with advanced CKD who receive PPIs need regular monitoring for potential complications, including electrolyte disturbances (e.g., hypomagnesemia) and drug‑drug interactions with other renally cleared medications. 1

General Treatment Principles in CKD‑Related Dyspepsia

• Clinicians should not assume that all dyspeptic symptoms in CKD are solely uremia‑related; standard evaluation and treatment algorithms apply, with appropriate renal dose adjustments for prescribed agents. 1